UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 92

Sortiert nach

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression

Blood, 2021-02, Vol.137 (6), p.763-774

2021

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors

Molecular therapy. Methods & clinical development, 2019-09, Vol.14, p.126-133

2019

Link zum Volltext

Verfügbarkeit prüfen

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients

Blood, 2013-02, Vol.121 (6), p.1039-1048

2013

Link zum Volltext

Verfügbarkeit prüfen

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs

The Journal of clinical investigation, 2022-11, Vol.132 (22), p.1-15

2022

Link zum Volltext

Verfügbarkeit prüfen

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

Blood, 2015-02, Vol.125 (7), p.1180-1188

2015

Link zum Volltext

Verfügbarkeit prüfen

Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages

Frontiers in immunology, 2022-07, Vol.13, p.894411-894411

2022

Link zum Volltext

Verfügbarkeit prüfen

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Blood, 2016-05, Vol.127 (19), p.2289-2297

2016

Link zum Volltext

Verfügbarkeit prüfen

Modulation of the liver immune microenvironment by the adeno-associated virus serotype 8 gene therapy vector

Molecular therapy. Methods & clinical development, 2021-03, Vol.20, p.95-108

2021

Link zum Volltext

Verfügbarkeit prüfen

Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays

Human gene therapy. Part B. Methods, 2019-04, Vol.30 (2), p.35

2019

Link zum Volltext

Verfügbarkeit prüfen

Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients

Journal of clinical medicine, 2023-03, Vol.12 (5), p.2080

2023

Link zum Volltext

Verfügbarkeit prüfen

Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency

Molecular therapy. Methods & clinical development, 2020-12, Vol.19, p.486-495

2020

Link zum Volltext

Verfügbarkeit prüfen

B-cell memory against factor VIII

Cellular immunology, 2016-03, Vol.301, p.49-58

Reipert, Birgit M.

2016

Link zum Volltext

Verfügbarkeit prüfen

Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model

Blood, 2011-09, Vol.118 (13), p.3698-3707

2011

Link zum Volltext

Verfügbarkeit prüfen

Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses

Hematology, 2014-12, Vol.2014 (1), p.372-378

Reipert, Birgit M

2014

Link zum Volltext

Verfügbarkeit prüfen

Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9

Blood, 2011-01, Vol.117 (1), p.259-267

2011

Link zum Volltext

Verfügbarkeit prüfen

PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development

Toxicologic pathology, 2015-10, Vol.43 (7), p.959-983

2015

Link zum Volltext

Verfügbarkeit prüfen

Blockade of the costimulatory CD28‐B7 family signal axis enables repeated application of AAV8 gene vectors

Journal of thrombosis and haemostasis, 2020-05, Vol.18 (5), p.1075-1080

2020

Link zum Volltext

Verfügbarkeit prüfen

Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells

Thrombosis and haemostasis, 2006-09, Vol.96 (3), p.309

2006

Link zum Volltext

Verfügbarkeit prüfen

FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors

Blood, 2016-07, Vol.128 (2), p.293-296

2016

Link zum Volltext

Verfügbarkeit prüfen

The soluble cytoplasmic tail of CD45 regulates T‐cell activation via TLR4 signaling

European journal of immunology, 2021-12, Vol.51 (12), p.3176-3185

2021

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A

Blood advances, 2024-06, Vol.8 (11), p.2726-2739

2024

Link zum Volltext

Verfügbarkeit prüfen

Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A

Blood, 2016-06, Vol.127 (26), p.3439-3449

2016

Link zum Volltext

Verfügbarkeit prüfen

The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A

Thrombosis research, 2023-11, Vol.231, p.112-120

2023

Link zum Volltext

Verfügbarkeit prüfen

How Full-Length FVIII Benefits from Its Heterogeneity – Insights into the Role of the B-Domain

Pharmaceutical research, 2019-05, Vol.36 (5), p.77-12, Article 77

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(89)
Buchkapitel
(3)

Sprache

Englisch
(92)
Japanisch
(11)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(51)
Science & Technology
(51)
Humans
(40)
Hematology
(31)
Animals
(26)
Factor Viii - Immunology
(21)
Mice
(19)
Hemophilia A - Immunology
(18)
Male
(15)
Biological And Medical Sciences
(14)
Factor Viii
(14)
Medical Sciences
(14)
Immunology
(13)
Hematologic And Hematopoietic Diseases
(12)
Hemophilia A
(11)
Biochemistry
(9)
Cardiovascular System & Cardiology
(9)
Cell Biology
(9)
Factor Viii - Therapeutic Use
(9)
Female
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression

Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Modulation of the liver immune microenvironment by the adeno-associated virus serotype 8 gene therapy vector

Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays

Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients

Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency

B-cell memory against factor VIII

Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model

Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses

Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9

PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development

Blockade of the costimulatory CD28‐B7 family signal axis enables repeated application of AAV8 gene vectors

Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells

FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors

The soluble cytoplasmic tail of CD45 regulates T‐cell activation via TLR4 signaling

Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A

Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor

Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A

The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A

How Full-Length FVIII Benefits from Its Heterogeneity – Insights into the Role of the B-Domain

Suchergebnisse filtern